ARTICLES BY ERIN HARRIS
How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing12/1/2022
Industry luminaries from Kite Pharma, Novartis Gene Therapies, and SwanBio share their knowledge on why the road to cost-efficient and timely commercial manufacturing for cell and gene therapies (CGTs) is paved with AI, automation, clinical trial design, AAV vector efficiencies, skilled team members, and more.
A Summary of Cell & Gene Therapies Market Outlook Report2/1/2022
A summary of ISR’s Cell & Gene Therapies Market Outlook research report highlights respondents’ manufacturing needs for both today and the near future.
What To Expect From Cell Therapy And Gene Therapy In 2022 And Beyond12/1/2021
From innovations in clinical development and manufacturing to the evaluation of investigational cell and gene therapies (CGTs), subject matter experts from Cellectis and Immatics share a brief look back on 2021 and a detailed glimpse into the near future of gene therapy and cell therapy respectively.
Inside The Planning Of Audentes' Future Manufacturing Facility3/1/2021
A Q&A regarding Audentes Therapeutics’ Sanford, NC future facility, which will manufacture the company’s portfolio of adeno-associated virus (AAV)-based gene therapies aimed at targeting serious rare neuromuscular diseases.
COVID-19 And Cell And Gene Sector: Contingency Planning For 2021 And Beyond12/1/2020
Some of the brightest luminaries representing the sector’s various subsets all answer the same question: As a result of COVID-19, how have you and your team had to pivot to ensure continued success in 2021 and beyond?
ARM’s Meeting on the Mesa 2020 — Disruptive Technologies that Will Change Cell Therapy10/19/2020
At ARM's Meeting on the Mesa 2020, I found the panel titled, Disruptive Technologies that Will Change the Cell Therapy Landscape, to be very informative. Here’s why.
Inside the Planning of Audentes’ Future Manufacturing Facility9/30/2020
Audentes’ Sanford, NC future facility, which will manufacture the company’s portfolio of adeno-associated virus-based gene therapies aimed at targeting serious rare neuromuscular diseases, is slated to be operational next year. Donald Wuchterl, Audentes’ Senior Vice President, Technical Operations talked to me about the best practices he and his team have implemented thus far in the planning stages, equipment needs, challenges and solutions, and more.
Driving Diversity And Inclusion In Life Sciences8/3/2020
Five experts weigh in on the status of diversity and inclusion in the life sciences industry and detail actions you can take now to drive awareness and change.
Cell & Gene And COVID-193/24/2020
As the world rushes to combat the novel coronavirus behind the COVID-19 pandemic outbreak, the cell and gene sector has been impacted.
Challenges Facing The Cell And Gene Sector’s Regulation Landscape11/27/2019
Here are the critical action items cell and gene therapy professionals should heed to keep pace with the sector’s ever-evolving regulations.
Potential Solutions To Current Pricing Models For Cell And Gene Therapies10/1/2019
Curative cell & gene therapies are changing modern medicine as we know it, but are their high price tags fair to the patient?
Tackling Cell & Gene Therapy Financing & Manufacturing Challenges7/1/2019
As interest in the cell and gene market continues to heat up, the sector’s manufacturing and finance challenges have become top priorities.
The Unique Demands of Cell and Gene Therapy Supply Chains3/1/2019
Three cell and gene therapy sector SMEs representing industry and academia explain supply chain challenges and viable solutions.